Skip to content
lifestyle.bossesmag.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
ALX Oncology
ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026
May 27, 2026
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
May 25, 2026
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer
May 24, 2026
ALX Oncology Announces Pricing of Underwritten Offering
January 30, 2026
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer
January 30, 2026